结46h)14d一周期(mFOLFOX6) 伊立替康180mg/m2ivgttd1+结酸结叶400mg/m2ivgttd1+尿氟 结结400mg/m2bolusiv,尿结结氟2400mg/m2civgtt(结结46h) 14d一周期 l 5-FU是结直结癌化结基石 l 沙利结、伊立替康自奥2000年后成结结 直结癌化结重要结成 ...
FOLFOX与FOLFIRI简介 5-FU -抗代谢类抗肿瘤药-抑制胸腺嘧啶核苷酸合成酶（TS酶），阻断脱氧尿嘧啶核苷酸转变 为脱氧胸腺嘧啶核苷酸，从而抑制DNA的生物合成-细胞周期特异性药物，S期 伊立替康 –植物碱类药物–伊立替康是半合成喜树碱的衍生物，是能特异性抑制DNA拓扑异构酶I的抗 肿瘤药–细胞周期特异性药物，S期...
3526#Background:Colorectal cancer (CRC) is a heterogenous disease treated with FOLFOX, FOLFIRI, and FOLFOXIRI chemotherapy regimens. About 85% of CRC patients have microsatellite stable (MSS) tumors that resist immune checkpoint blockade (ICB). Some studies suggest that chemotherapy modulates the MSS...
Triplet Chemotherapy (FOLFOXIRI) Plus Bevacizumab Versus Doublet Chemotherapy (FOLFOX/FOLFIRI) Plus Bevacizumab in Conversion Therapy for Metastatic Colore... Triplet Chemotherapy (FOLFOXIRI) Plus Bevacizumab Versus Doublet Chemotherapy (FOLFOX/FOLFIRI) Plus Bevacizumab in Conversion Therapy for Metastatic ...
FOLFOX与FOLFIRI简介 5-FU 抗代谢类抗肿瘤药 抑制胸腺嘧啶核苷酸合成酶(TS酶),阻断脱氧尿嘧啶核苷酸转变为脱氧胸腺嘧啶核苷酸,从而抑制DNA的生物合成 细胞周期特异性药物,S期 伊立替康 植物碱类药物 伊立替康是半合成喜树碱的衍生物,是能特异性抑制DNA拓扑异构酶I的抗肿瘤药 ...
chemotherapy10 (16%)3 (16%)1 (20%)Biologic**26 (41%)3 (16%)1 (20%)Pembrolizumab4 (6%)4 (21%)0 (0%)*FOLFOX, FOLFIRI, CAPOX, or CAPIRI... W Phillips,M Alrehaili,H Marginean,... - 《Journal of Clinical Oncology》 被引量: 0发表: 2024年 CAPIRI plus bevacizumab (CAPIRI-B...
广州医学院 硕士学位论文 FOLFOX、FOLFIRI方案在进展期直肠癌新辅 助化疗中的应用研究 研究生：宋靖方 导师：雷建教授 申请学位级别：医学硕士年级：2009级 学科专业：普通外科学研究方向：胃肠疾病 论文提交日期：2012年5月论文答辩日期：2012年5月 学位类型：医学专业学位学位授予单位：广州医学院 2012年5月 ...
FOLFIRI is a chemotherapy regimen that consists of irinotecan, infusional 5-FU, and leucovorin. It is used in the treatment of previously untreated metastatic colorectal cancer and has shown comparable efficacy to other chemotherapy regimens like FOLFOX. ...
Modified FOLFIRI as Second-Line Chemotherapy after Failure of Modified FOLFOX-4 in Advanced Gastric Cancer The purpose of this study was to evaluate efficacy and toxicity of irinotecan, leucovorin and 5-fluorouracil (FOLFIRI) as second-line treatment after failu... Eun,Kyoung,Jeon,... - 《Cancer...
LBA3_PR'Randomized, non-inferiority, phase III trial of second-line chemotherapy for metastatic colorectal cancer (mCRC), comparing the efficacy and safety of XELIRI + bevacizumab versus FOLFIRI + bevacizumab (AXEPT)'[J]. Annals of Oncol, 2017, 28 (Supplement 10). [33] Haller DJ, Cassidy ...